Results 201 to 210 of about 1,127,844 (304)

Differentiated Thyroid Carcinoma

, 2021
openaire   +1 more source

Data‐Independent Acquisition Mass Spectrometry in Tumor Classification and Cancer Biomarker Research

Mass Spectrometry Reviews, EarlyView.
Abstract Cancer treatment is far from optimal also because current classification systems do not reflect the complex molecular status of the tumor and its phenotype in sufficient detail. To construct molecular tumor classifiers, omics tools provide complex molecular data reflecting many aspects from genotype to phenotype.
Jan Simonik, Petr Lapcik, Pavla Bouchalova, Pavel Bouchal   +3 more
wiley   +1 more source

Parity as a Risk Factor for Differentiated Thyroid Carcinoma: A Population-based Study.

J Clin Endocrinol Metab
Dan R, Paran N, Vinegrad N, Fraenkel M, Yoel U.   +4 more
europepmc   +1 more source

P53 loss and BRAF V600E mutation suggest potentially divergent pathways to aggressiveness in high grade differentiated thyroid carcinoma. [PDF]

Discov Oncol
Cui J, Li C, Liu X, Duan J.
europepmc   +1 more source

Analysis of Carbohydrates and Glycoconjugates by Matrix‐Assisted Laser Desorption/Ionization Mass Spectrometry: An Update for 2023–2024

Mass Spectrometry Reviews, EarlyView.
ABSTRACT The use of MALDI mass spectrometry for the analysis of carbohydrates and glycoconjugates is a well‐established technique and this comprehensive review is the twelfth update of the original article published in 1999 and brings coverage of the literature to the end of 2024.
David J. Harvey
wiley   +1 more source

Levothyroxine dose prediction post-thyroidectomy for differentiated thyroid carcinoma. [PDF]

Front Endocrinol (Lausanne)
Ma L, Xie Y, Ke S, Liu D, Wang L, Wang L, Liu L.   +6 more
europepmc   +1 more source

Organoid Coculture Models for Cancer Research and Immunotherapy

Med Research, EarlyView.
This review summarizes organoid coculture platforms, including submerged Matrigel culture, air–liquid interface, microfluidic/organoid‐on‐a‐chip, and 3D bioprinting, for reconstructing the tumor microenvironment to study tumor–stroma/immune crosstalk, evaluate immunotherapies, and enable drug screening.
Zhuo Yang, Huihui Yang, Guangxin Li, Guobang Liu, Zhulan Chen, Wenzhi Tian, Meiyang Huang, Xiaoling Liu, Yongsheng Zhao, Dong Chen   +9 more
wiley   +1 more source

Association between clinical and pathological factors and risk of radioiodine refractory in patients with differentiated thyroid carcinoma. [PDF]

Front Endocrinol (Lausanne)
Rakhmankulova A, Pak L, Pivina L, Burkitbayev Z, Orekhov A, Pak D, Bolsynbekova S, Pivin M, Seitkhanova D, Kudaiberdinov K, Dyussupov A, Nakashima M.   +11 more
europepmc   +1 more source

BRAF and MEK inhibitors in the treatment of aggressive thyroid carcinomas [PDF]

, 2008
Salerno, Paolo
core   +1 more source

NKX2‐1 Downstream Regulatory Structural Variants Explain a Substantial Proportion of Molecular Diagnoses in Patients With Benign Hereditary Chorea

Movement Disorders, EarlyView.
Abstract Background NKX2‐1–related disorders (NKX2‐1‐RDs) classically present with a triad of neurological, endocrine, and pulmonary manifestations, including benign hereditary chorea. However, in a fraction of patients, NKX2‐1 coding variants are not detected, and variants outside the NKX2‐1 locus have been reported.
Robin Wijngaard, Lucy Dougherty‐de Miguel, German Demidov, Galuh Astuti, Amaia Lasa‐Aranzasti, Ana Cueto‐González, Marta Correa‐Vela, Carlos Lázaro‐Hernández, Charlotte A. Haaxma, Clara D.M. van Karnebeek, David Gómez‐Andrés, Ignacio Iglesias‐Serrano, Jiddeke M. van de Kamp, Jolanda Schieving, Laura Trujillano, Marc Engelen, Beatriz Muñoz‐Cabello, Roderick P.P.W.M. Maas, Thatjana Gardeitchik, Victoria Gonzalez, Annemarie de Vreugd, Cristina Pérez‐Sanchez, Elisabet Lloveras, Erik‐Jan Kamsteeg, Maartje Pennings, Natalia Rey‐Viñets, Javier Sánchez, Ronald van Beek, Antonio Moreno‐Galdó, Lisenka E.L.M. Vissers, Kornelia Neveling, Anna Marcé‐Grau, Machteld M. Oud, Belén Pérez‐Dueñas   +33 more
wiley   +1 more source